Vavricka Stephan R, Rogler Gerhard
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital Zürich, Zürich, Switzerland.
Swiss Med Wkly. 2009 Sep 19;139(37-38):527-34. doi: 10.4414/smw.2009.12520.
During the last few years significant advances have been achieved in the understanding of the pathogenesis of inflammatory bowel disease (IBD). A genetic susceptibility to Crohn's disease has been proven by identification of variations as risk factor NOD2/CARD15. Functional data on NOD2/CARD15 and NF-kappaB activation indicate that an inflammatory reaction of the intestinal mucosa, as an immediate response of the innate immune system, may be necessary for the maintenance of gut homeostasis. Crohn's disease is now also discussed as an impaired and inadequate immune reaction and no longer only as a hyper-responsiveness of the mucosal immune system. Data on NOD2/CARD15 expression suggest that macrophages and epithelial cells could be the locus of the primary pathophysiological defect and that T-cell activation might just be a secondary effect inducing chronification of the inflammation, perhaps as backup mechanism to insufficient innate immunity. In addition to NOD2/CARD15 there are more "innate" pathways by which commensal and pathogenic bacteria can directly be hindered to invade the human body (such as interaction with Toll like receptors, TLRs and defensins). The "germ-concept" and the "genetic concept" of IBD pathophysiology are converging. However, more time is needed until these important insights in IBD pathogenesis will make their way into routine diagnostic procedures and treatment of patients with IBD.
在过去几年中,我们对炎症性肠病(IBD)发病机制的理解取得了重大进展。通过鉴定NOD2/CARD15变异作为危险因素,已证实克罗恩病存在遗传易感性。关于NOD2/CARD15和NF-κB激活的功能数据表明,肠道黏膜的炎症反应作为先天免疫系统的即时反应,可能是维持肠道内环境稳定所必需的。现在,克罗恩病也被视为一种受损且不充分的免疫反应,而不再仅仅被看作是黏膜免疫系统的过度反应。关于NOD2/CARD15表达的数据表明,巨噬细胞和上皮细胞可能是主要病理生理缺陷的所在部位,而T细胞激活可能只是诱导炎症慢性化的次要效应,也许是作为先天免疫不足的备用机制。除了NOD2/CARD15外,还有更多“先天”途径,共生菌和病原菌可通过这些途径直接被阻止侵入人体(如与Toll样受体、TLRs和防御素的相互作用)。IBD病理生理学的“细菌概念”和“遗传概念”正在趋同。然而,在IBD发病机制方面的这些重要见解应用于IBD患者的常规诊断程序和治疗之前,还需要更多时间。